Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Elevated levels of immunoglobuline E in blood are said to promote the occurence of atopic dermatitis; in fact, many patients with atopic dermatitis have high IgE levels. This study tried to explore whether the depletion of IgE from blood and skin might result in a change of immunological parameters and might alter the clinical course of the disease.
An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis.
Study Start Date :
Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
aged between 12 and 60 years
clinical diagnosis of AD (criteria of Hanifin and Rajka, 1980)
serum IgE between 30 and 1,300 IU/ml
at least one significantly positive RAST
a positive skin prick test of the same specificity as the RAST
an Investigator`s Global Assessment Score of 2 or more at randomization
stable AD, as defined as active AD (IGA 2 or more) for > 9 months per year
signed informed consent.
pregnant or nursing females or women of childbearing potential who did not use a reliable contraceptive method
treatment with omalizumab within the last 12 months before study treatment
known hypersensitivity to any ingredients of omalizumab or omalizumab- related drugs
elevated serum IgE levels for reasons other than atopy
use of long-acting antihistamine astemizol within 3 months prior to visit1
use of medium-acting antihistamines (e.g. loratadine, cetirizine) within 5 days prior to visit 1
use of short-acting antihistamines (e.g. diphenhydramin, terfenadine) within 3 days prior to visit 1
use of zafirlukast or other leukotriene receptor inhibitors and zileuton or other 5-lipoxygenase enzyme inhibitors within 3 days prior to visit 1
use of phototherapy or systemic therapy that is known or suspected to have had an effect on AD within 1 month prior to first application of study medication
treatment with topical therapy (other than hydrocortisone 1%) that is known or suspected to have had an effect on AD within 14 days prior to first application of study medication
use of systemic steroids (oral, intravenous, including intraarticular and rectal) within one month prior to first application of study medication. (Patients on a stable maintenance dose of inhaled steroids were allowed to participate)
use of systemic antibiotics within 2 weeks prior to first application of study medication
use of tranquilizers, hypnotic agents or tricyclic antidepressants within 2 weeks prior to the start of the study
immunocompromised patients or patients having a history of malignant disease
concurrent skin diseases
active bacterial, viral or fungal infections that required treatment with a prohibited medication
a history of recurrent herpes simplex infection having active lesions at baseline
tinea corporis / tinea cruris
clinically significant laboratory abnormalities
a history of noncompliance to medical regimens and patients who were considered potentially unreliable
evidence of drug or alcohol abuse or other factors limiting ability to fully cooperate
any condition or prior/continuing treatment which, in the opinion of the investigator, should have rendered the patient ineligible for the study.